haku: @indexterm bio-technology / yhteensä: 177
viite: 10 / 177
| Tekijä: | Wuyts, S. Dutta, S. |
| Otsikko: | Licensing exchange - Insights from the biopharmaceutical industry |
| Lehti: | International Journal of Research in Marketing
2008 : DEC, VOL. 25:4, p. 273-281 |
| Asiasana: | pharmaceutical industry bio-technology licensing networks models |
| Vapaa asiasana: | disclosure of information |
| Kieli: | eng |
| Tiivistelmä: | For dedicated technology firms (henceforth as: dt-firms), licensing out technologies is a main source of revenue. This study's starting point is that the variation among dt-firms of the number of new obtained licensing deals can be explained by their voluntary disclosure (here as: vol-dscl.) of strategic information (here as: str-info) and their position in the industry's licensing and social networks. Based on empirical study of the biopharmaceutical industry, it is shown that, whereas vol-dscl. str-info makes it possible for dt-firms in the biotechnology (as: bio-tech.) to sign more new licensing deals, firms should be careful not to disclose too much str-info. Dt-firms in the bio-tech. with more central positions in the licensing exchange network get more new licensing deals. However, again, the effect has an inverted-U shape, indicating a dark side of network centrality. There is provided evidence that licensing exchange is socially embedded. A central position in the social network of board interlocks leads to more new licensing deals. Dt-firms can use these insights to address practical questions, e.g. how much str-info they should uncover, as well as to set long-term directions regarding network position. |
SCIMA